Global Next-Generation Gynecological Cancer Diagnostics Market to Reach $5.66 Billion by 2031
This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
In 2020, the global next-generation gynecological cancer diagnostics market was valued at $1,976.5 million, which is expected to reach $5,657.7 million by 2031, growing at a CAGR of 10.07% during the forecast period 2021-2031.
Market Report Coverage - Next-Generation Gynecological Cancer Diagnostics
Market Segmentation
- By Product Type - Products and Services
- By Technology - Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Others
- By Indication - Ovarian Cancer, Cervical Cancer, and Uterine Cancer
- By End User - Hospitals and Ambulatory Centers, Diagnostic Laboratories, Academic and Research Institutes, and Other End Users
Regional Segmentation
- North America - U.S., Canada
- Europe - Germany, U.K., France, Italy, Spain, The Netherlands, and Rest-of-Europe
- Asia-Pacific - China, Australia, Japan, India, South Korea, and Rest-of-Asia-Pacific
- Latin America - Mexico, Brazil, and Rest-of-Latin-America
- Rest-of-the-World
Market Growth Drivers
- Subsequent Decline in Next-Generation Sequencing (NGS) Cost
- Increased Recommendations from Government Organizations and Scientific Societies
- Increased Awareness and Shift Toward Personalized Medicine
Market Challenges
- Limited Food and Drug Administration (FDA) Approved Next-Generation Sequencing (NGS) tests
- Complexities Involved with Overall Next-Generation Sequencing (NGS) Process and Result Interpretation
- Reimbursement Challenges Across the Countries
Market Opportunities
- Increased Market Investments and Government Funded Projects
- Next-Generation Sequencing (NGS) Acceptance by Emerging Nations
Key Companies Profiled
Agilent Technologies, Inc., ARUP Laboratories, BGI Genomics, CENTOGENE N.V., F. Hoffmann-La Roche Ltd, Fulgent Genetics, Inc., Illumina, Inc., Invitae Corporation, Konica Minolta, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.
Key Questions Answered in the Report
- Which gynecological cancers have been considered in the report?
- What are the key milestones in the development of next-generation gynecological cancer diagnostics?
- What is the scope of next-generation gynecological cancer diagnostics in the future?
- What are the major market drivers, restraints, and opportunities in the global next-generation gynecological cancer diagnostics market?
- What are the key developmental strategies that are being implemented by the key players to sustain this market?
- What is the impact of COVID-19 on the next-generation gynecological cancer diagnostics market?
- What are the guidelines implemented by different government bodies to regulate the approval of next-generation gynecological cancer diagnostics panels and assays?
- How are next-generation gynecological cancer diagnostics being utilized for the development of personalized medicine?
- What is the role of biomarkers in next-generation gynecological cancer diagnostics?
- How will the investments by public and private companies and government organizations affect the global next-generation gynecological cancer diagnostics market?
- What was the market size of the leading segments and sub-segments of the global next-generation gynecological cancer diagnostics market in 2020?
- How will the industry evolve during the forecast period 2021-2031?
- What will be the growth rate of the next-generation gynecological cancer diagnostics market during the forecast period 2021-2031?
- How will each of the segments of the global next-generation gynecological cancer diagnostics market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2031?
- What is the market size of the next-generation gynecological cancer diagnostics market in different countries of the world?
- Which region is expected to contribute to the highest sales of the next-generation gynecological cancer diagnostics market?
- What are the reimbursement scenarios and regulatory structures for the next-generation gynecological cancer diagnostics market in different regions?
- What are the key strategies incorporated by the players of the global next-generation gynecological cancer diagnostics market to sustain the competition and retain their supremacy?
Market Overview
Ovarian, cervical, and uterine cancer are the most common gynecological malignancies among women worldwide. Cervical cancer is the fourth most frequently occurring cancer in women. It is anticipated that cervical cancer cases will increase from approximately 580,000 in 2018 to 700,000 in 2030, with a rise in the annual number of deaths from 311,000 to 400,000. Gynecological cancers are a result of genomic aberrations controlled by epigenetic factors, acquired and heritable mutations, and transcriptional deviations. A comprehensive understanding of the genomic and molecular framework of gynecologic malignancies is critical in the evolution of potent biomarkers for detection and prevention, molecular profiling, and the development of personalized treatment strategies.
Traditionally, genetic analysis of gynecological malignancies was carried out by analyzing small, single portions of deoxyribonucleic acid (DNA), referred to as Sanger sequencing. Advanced molecular genetic testing, including next-generation sequencing, microarray, polymerase chain reaction, have contributed significantly to deciphering the molecular profile of gynecological cancers in recent years. Advancements in the field of sequencing technologies have supported researchers and clinicians to harness knowledge pertaining to these underlying mutations, which further helped the stakeholders to discover biomarkers for guiding targeted therapeutic decisions.
The purpose of this study is to gain a holistic view of the next-generation gynecological cancer diagnostics market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The study defines the products and services utilized for next-generation gynecological cancer diagnostics to improve prognosis and quality of life among women. Mutation molecular profiling is critical for the identification and characterization of unique mutations to facilitate disease manifestation and progression. Comprehensive profiling of biological samples, particularly blood and tissues, can help researchers and clinicians identify specific biomarkers that signify a particular disease. The study aims at deciphering the potential of next-generation gynecological cancer diagnostics in the field of research and diagnostics and its critical role in bolstering the current genomic era to enable personalized medicine in routine healthcare settings.
The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well. It also aims at answering various aspects of the global next-generation gynecological cancer diagnostics market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion.
Within the research report, the market has been segmented into ‘product type,’ ‘technology,’ ‘indication,’ ‘end user,’ and ‘regions.’. Each of these segments covers the inclination of the market revenue, underlying patterns, snapshot of the market over the projected years, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The global next-generation gynecological cancer diagnostics market is currently budding due to the presence of various juggernauts such as Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc., BGI, and PerkinElmer Inc., as well as other medium and small-medium enterprises, that are offering a wide range of next-generation gynecological cancer diagnostics products and services in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.
Table of Contents
1 Definition
1.1 Inclusion and Exclusion Criteria
1.1.1 Inclusions
1.1.2 Exclusions
2 Research Scope
2.1 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Next-Generation Gynecological Cancer Diagnostics Market: Research Methodology
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4 Market
4.1 Introduction
4.2 Molecular Profiling and Techniques
4.3 Role of Molecular Diagnostics in Gynecological Cancers
4.4 Diagnostic Technologies and Regulatory Landmarks Timeline in Gynecological Cancers
4.5 Emerging Molecular Testing in Gynecological Cancer
4.6 Current Market Size and Growth Potential, $Million, 2021-2031
5 Role of Biomarkers in Gynecological Cancer
5.1 Introduction
5.2 Predictive Molecular Testing in Gynecological Cancer
5.3 Companion Diagnostics (CDx)
6 COVID-19 Impact on Global Next-Generation Gynecological Cancer Diagnostics Market
6.1 Impact on Supply Chain and Operations
6.2 COVID-19 Impact: Global Next-Generation Gynecological Cancer Diagnostics Market
6.3 Pre- and Post-COVID-19 Impact Assessment
7 Market Dynamics
7.1 Overview
7.2 Impact Analysis
7.3 Market Drivers
7.3.1 Subsequent Decline in Next-Generation Sequencing (NGS) Cost
7.3.2 Increased Recommendations from Government Organizations and Scientific Societies
7.3.3 Increased Awareness and Shift Toward Personalized Medicine
7.4 Market Restraints
7.4.1 Limited Food and Drug Administration (FDA) Approved Next-Generation Sequencing (NGS) tests
7.4.2 Complexities Involved with Overall Next-Generation Sequencing (NGS) Process and Result Interpretation
7.4.3 Reimbursement Challenges Across the Countries
7.5 Market Opportunities
7.5.1 Increased Market Investments and Government Funded Projects
7.5.2 Next-Generation Sequencing (NGS) Acceptance by Emerging Nations
8 Industry Insights
8.1 Overview
8.2 Legal Requirements and Framework in the U.S.
8.2.1 FDA Regulation
8.2.2 CMS Regulation
8.3 Legal Requirements and Framework in Europe
8.4 Legal Requirements and Framework in Asia-Pacific
8.4.1 China
8.4.2 Japan
8.5 Reimbursement Scenario
8.6 Funding Scenario
9 Market Segmentation
9.1 Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), $Million, 2020-2031
9.1.1 Overview
9.1.1.1 Polymerase Chain Reaction (PCR)
9.1.1.1.1 by Value
9.1.1.1.2 by Volume
9.1.1.2 Next-Generation Sequencing (NGS)
9.1.1.2.1 by Value
9.1.1.2.2 by Volume
9.1.1.2.3 Broad Panels
9.1.1.2.3.1 by Value
9.1.1.2.3.2 by Volume
9.1.1.2.4 Targeted Gene Panels
9.1.1.2.4.1 by Value
9.1.1.2.4.2 by Volume
9.1.1.2.5 Single Gene Panels
9.1.1.2.5.1 by Value
9.1.1.2.5.2 by Volume
9.1.1.3 Other Technologies
9.1.1.3.1 by Value
9.1.1.3.2 by Volume
10 Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), $Million, 2020-2031
10.1 Overview
10.2 Services
10.3 Products
11 Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), $Million, 2020-2031
11.1 Overview
11.2 Ovarian Cancer
11.3 Cervical Cancer
11.4 Uterine Cancer
12 Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), $Million, 2020-2031
12.1 Overview
12.2 Academic and Research Institutes
12.3 Hospitals and Ambulatory Centers
12.4 Diagnostic Laboratories
12.5 Other End Users
13 Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), $Million, 2020-2031
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.2 Canada
13.3 Europe
13.3.1 Germany
13.3.2 U.K.
13.3.3 France
13.3.4 Italy
13.3.5 Spain
13.3.6 Netherlands
13.3.7 Rest-of-Europe
13.4 Asia-Pacific
13.4.1 China
13.4.2 Japan
13.4.3 India
13.4.4 Australia
13.4.5 South Korea
13.4.6 Rest-of-Asia-Pacific
13.5 Latin America
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Rest-of-Latin America
13.6 Rest-of-the-World (RoW)
14 Competitive Landscape and Company Profiles
14.1 Competitive Landscape
14.2 Regulatory and Legal Activities
14.3 Synergistic Activities
14.4 Mergers and Acquisitions
14.5 Product Launches
14.6 Business Expansions
14.7 Market Share Analysis, by Service Providers, 2020
14.8 Market Share Analysis, by Product Manufacturers, 2020
14.9 Growth Share Analysis, by Company, 2019-2020
14.9.1 Growth Share Analysis, by Service Providers, 2019-2020
14.9.2 Growth Share Analysis, by Product Manufacturers, 2019-2020
15 Company Profiles
15.1 Overview
15.2 Agilent Technologies, Inc.
15.2.1 Company Overview
15.2.2 Role of Agilent Technologies, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.2.3 Key Customers of the Company
15.2.4 Key Competitors of the Company
15.2.5 Financials
15.2.6 Key Insights About Financial Health of the Company
15.2.7 Business Strategies
15.2.8 SWOT Analysis
15.3 ARUP Laboratories
15.3.1 Company Overview
15.3.2 Role of ARUP Laboratories in the Global Next-generation gynecological Cancer Diagnostics Market
15.3.3 Key Customers of the Company
15.3.4 Key Competitors of the Company
15.3.5 SWOT Analysis
15.4 BGI Genomics
15.4.1 Company Overview
15.4.2 Role of BGI Genomics in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.4.3 Key Customers of the Company
15.4.4 Key Competitors of the Company
15.4.5 Business Strategies
15.4.6 SWOT Analysis
15.5 CENTOGENE N.V.
15.5.1 Company Overview
15.5.2 Role of CENTOGENE N.V. in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.5.3 Key Customers of the Company
15.5.4 Key Competitors of the Company
15.5.5 Financials
15.5.6 Key Insights About Financial Health of the Company
15.5.7 SWOT Analysis
15.6 F. Hoffmann-La Roche Ltd
15.6.1 Company Overview
15.6.2 Role of F. Hoffmann-La Roche Ltd in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.6.3 Key Customers of the Company
15.6.4 Key Competitors of the Company
15.6.5 Financials
15.6.6 Key Insights About Financial Health of the Company
15.6.7 Business Strategies
15.6.8 SWOT Analysis
15.7 Fulgent Genetics, Inc.
15.7.1 Company Overview
15.7.2 Key Customers of the Company
15.7.3 Key Competitors of the Company
15.7.4 Financials
15.7.5 Key Insights About Financial Health of the Company
15.7.6 Business Strategies
15.7.7 SWOT Analysis
15.8 Illumina, Inc.
15.8.1 Company Overview
15.8.2 Role of Illumina, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.8.3 Key Customers of the Company
15.8.4 Key Competitors of the Company
15.8.5 Financials
15.8.6 Key Insights About Financial Health of the Company
15.8.7 SWOT Analysis
15.9 Invitae Corporation
15.9.1 Company Overview
15.9.2 Role of Invitae Corporation in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.9.3 Key Customers of the Company
15.9.4 Key Competitors of the Company
15.9.5 Financials
15.9.6 Key Insights About Financial Health of the Company
15.9.7 Business Strategies
15.9.8 SWOT Analysis
15.1 Konica Minolta, Inc.
15.10.1 Company Overview
15.10.2 Role of Konica Minolta, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.10.3 Key Customers of the Company
15.10.4 Key Competitors of the Company
15.10.5 Financials
15.10.6 Key Insights About Financial Health of the Company
15.10.7 Business Strategies
15.10.8 SWOT Analysis
15.11 Laboratory Corporation of America Holdings
15.11.1 Company Overview
15.11.2 Role of Laboratory Corporation of America Holdings in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.11.3 Key Customers of the Company
15.11.4 Key Competitors of the Company
15.11.5 Financials
15.11.6 Business Strategies
15.11.7 SWOT Analysis
15.12 Myriad Genetics, Inc.
15.12.1 Company Overview
15.12.2 Role of Myriad Genetics, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.12.3 Key Customers of the Company
15.12.4 Key Competitors of the Company
15.12.5 Financials
15.12.6 SWOT Analysis
15.13 OPKO Health, Inc.
15.13.1 Company Overview
15.13.2 Role of OPKO Health, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.13.3 Key Customers of the Company
15.13.4 Key Competitors of the Company
15.13.5 Financials
15.13.6 Key Insights About Financial Health of the Company
15.13.7 SWOT Analysis
15.14 QIAGEN N.V
15.14.1 Company Overview
15.14.2 Role of QIAGEN N.V. in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.14.3 Key Customers of the Company
15.14.4 Key Competitors of the Company
15.14.5 Financials
15.14.6 Key Insights About Financial Health of the Company
15.14.7 Business Strategies
15.14.8 SWOT Analysis
15.15 Quest Diagnostics Incorporated
15.15.1 Company Overview
15.15.2 Role of Quest Diagnostics Incorporated in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.15.3 Key Customers of the Company
15.15.4 Key Competitors of the Company
15.15.5 Financials
15.15.6 SWOT Analysis
15.16 Thermo Fisher Scientific Inc.
15.16.1 Company Overview
15.16.2 Role of Thermo Fisher Scientific Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.16.3 Key Customers of the Company
15.16.4 Key Competitors of the Company
15.16.5 Financials
15.16.6 Key Insights About Financial Health of the Company
15.16.7 SWOT Analysis
Emerging companies
15.17 Overview
15.18 NgeneBio
15.18.1 Company Overview
15.18.2 Role of NgeneBio in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.19 oncgnostics GmbH
15.19.1 Company Overview
15.19.2 Role of oncgnostics GmbH in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.2 Self-screen B.V.
15.20.1 Company Overview
15.20.2 Role of Self-screen B.V. in the Global Next-Generation Gynecological Cancer Diagnostics Market
15.21 Strata Oncology, Inc.
15.21.1 Company Overview
15.21.2 Role of Strata Oncology, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
List of Figures
Figure 1: Impact Analysis of Market Drivers and Opportunities in Global Next-Generation Gynecological Cancer Diagnostics Market
Figure 2: Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), 2020 and 2031
Figure 3: Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), 2020 and 2031
Figure 4: Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), 2020 and 2031
Figure 5: Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), 2020 and 2031
Figure 6: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), 2020-2031
Figure 7: Global Next-Generation Gynecological Cancer Diagnostics Market Segmentation
Figure 8: Figure: Global Next-Generation Gynecological Cancer Diagnostics Market: Methodology
Figure 9: Figure: Bottom-Up Approach (Segment-Wise Analysis)
Figure 10: Figure: Top-Down Approach (Segment-Wise Analysis)
Figure 11: Cervical Cancer, Incidence Cases and New Cases (2008-2018)
Figure 12: Ovarian Cancer, Incidence Cases and New Cases (2008-2018)
Figure 13: Molecular Diagnostics Evolution Timeline
Figure 14: Types of Molecular Diagnostics Technologies
Figure 15: Diagnostic Technologies and Regulatory Landmark Timeline
Figure 16: Type of Non-Invasive Next Generation Novel Molecular Diagnostics
Figure 17: Evolution of Sequencing Technologies
Figure 18: Difference Between Polymerase Chain reaction (PCR) Across Three Generation Sequencing
Figure 19: Global Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 20: Potential Biomarkers for Gynecological Cancer Detection
Figure 21: Number of Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx), (1998–2020)
Figure 22: Number of Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx) Assays by Analytical Platform/Technology
Figure 23: Laboratory Setting and Testing Methodologies Being Adopted by the Respondent’s Laboratories
Figure 24: Types of Molecular Testing for Cancer Performed
Figure 25: Global Next-Generation Gynecological Cancer Diagnostics Market: COVID-19 Impact
Figure 26: Impact of COVID-19 on Global Next-Generation Gynecological Cancer Diagnostics Market
Figure 27: Global Next-Generation Gynecological Cancer Diagnostics, Market Dynamics
Figure 28: Impact Analysis of Market Drivers and Opportunities on Global Next-Generation Gynecological Cancer Diagnostics Market
Figure 29: Cost per Human Genome (2014–2021)
Figure 30: Approved Number of Personalized Medicine (2016–2020)
Figure 31: Percentage of Food and Drug Administration (FDA) Approved Personalized Medicines (2015–2020)
Figure 32: Next-Generation Sequencing (NGS) for Human Papillomavirus (HPV) Detection and Characterization Process Steps
Figure 33: Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), 2020 and 2031
Figure 34: Global Next-Generation Gynecological Cancer Diagnostics Market (Polymerase Chain Reaction (PCR)), $Million, 2020-2031
Figure 35: Global Next-Generation Gynecological Cancer Diagnostics Market (Polymerase Chain Reaction (PCR)), Thousand Units, 2020-2031
Figure 36: Global Next-Generation Gynecological Cancer Diagnostics Market (Next-Generation Sequencing (NGS)), $Million, 2020-2031
Figure 37: Global Next-Generation Gynecological Cancer Diagnostics Market (Next-Generation Sequencing (NGS)), Thousand Units, 2020-2031
Figure 38: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Broad Panels), $Million, 2020-2031
Figure 39: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Broad Panels), Thousand Units, 2020-2031
Figure 40: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Targeted Gene Panels), $Million, 2020-2031
Figure 41: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Targeted Gene Panels), Thousand Units, 2020-2031
Figure 42: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Single Gene Panels), $Million, 2020-2031
Figure 43: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Single Gene Panels), Thousand Units, 2020-2031
Figure 44: Global Next-Generation Gynecological Cancer Diagnostics Market (Other Technologies), $Million, 2020-2031
Figure 45: Global Next-Generation Gynecological Cancer Diagnostics Market (Other Technologies), Thousand Units, 2020-2031
Figure 46: Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), 2020 and 2031
Figure 47: Global Next-Generation Gynecological Cancer Diagnostics Market (Services), $Million, 2020-2031
Figure 48: Global Next-Generation Gynecological Cancer Diagnostics Market (Products), $Million, 2020-2031
Figure 49: Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), 2020 and 2031
Figure 50: Global Next-Generation Gynecological Cancer Diagnostics Market (Ovarian Cancer), $Million, 2020-2031
Figure 51: Global Next-Generation Gynecological Cancer Diagnostics Market (Cervical Cancer), $Million, 2020-2031
Figure 52: Global Next-Generation Gynecological Cancer Diagnostics Market (Uterine Cancer), $Million, 2020-2031
Figure 53: Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), 2020 and 2031
Figure 54: Global Next-Generation Gynecological Cancer Diagnostics Market (Academic and Research Institutes), $Million, 2020-2031
Figure 55: Global Next-Generation Gynecological Cancer Diagnostics Market (Hospitals and Ambulatory Centers), $Million, 2020-2031
Figure 56: Global Next-Generation Gynecological Cancer Diagnostics Market (Diagnostic Laboratories), $Million, 2020-2031
Figure 57: Global Next-Generation Gynecological Cancer Diagnostics Market (Other End Users), $Million, 2020-2031
Figure 58: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region)
Figure 59: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), 2020-2031
Figure 60: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), $Million, 2020-2031
Figure 61: North America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 62: North America, Market Dynamics
Figure 63: North America Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031
Figure 64: U.S. Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 65: Canada Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 66: Europe Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 67: Europe, Market Dynamics
Figure 68: Europe Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031
Figure 69: Germany Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 70: U.K. Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 71: France Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 72: Italy Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 73: Spain Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 74: Netherlands Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 75: Rest-of-Europe Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 76: Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 77: APAC, Market Dynamics
Figure 78: APAC Next-Generation Gynecological Market (by Country), 2020-2031
Figure 79: China Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 80: Japan Next-Generation Cancer Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 81: India Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 82: Australia Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 83: South Korea Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 84: RoAPAC Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 85: Latin America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 86: Latin America, Market Dynamics
Figure 87: Latin America Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031
Figure 88: Brazil Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 89: Mexico Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 90: Rest-of-Latin America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 91: RoW Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 92: Share of Key Developments and Strategies, January 2019–January 2022
Figure 93: Share of Regulatory and Legal Activities (by Company), January 2019–January 2022
Figure 94: Share of Synergistic Activities (by Company), January 2019–January 2022
Figure 95: Share of Mergers and Acquisitions (by Company), January 2019–January 2022
Figure 96: Share of Product Launches (by Company), January 2019–January 2022
Figure 97: Share of Business Expansions (by Company), January 2019–January 2022
Figure 98: Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market (by Service Providers), 2020
Figure 99: Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market (by Manufacturers), 2020
Figure 100: Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by Service Providers), 2020
Figure 101: Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by Product Manufacturers), 2020
Figure 102: Shares of Key Company Profiles
Figure 103: Agilent Technologies, Inc.: Product Portfolio
Figure 104: Agilent Technologies, Inc.: Overall Financials/Revenue, $Million, 2019-2021
Figure 105: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 106: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 107: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 108: Agilent Technologies, Inc.: SWOT Analysis
Figure 109: ARUP Laboratories: Service Portfolio
Figure 110: ARUP Laboratories: SWOT Analysis
Figure 111: BGI Genomics: Product Portfolio
Figure 112: BGI Genomics: SWOT Analysis
Figure 113: CENTOGENE N.V.: Service Portfolio
Figure 114: CENTOGENE N.V.: Overall Financials/Revenue, $Million, 2018-2020
Figure 115: CENTOGENE N.V.: Revenue (by Business Segment), $Million, 2018-2020
Figure 116: CENTOGENE N.V.: Revenue (by Region), $Million, 2018-2020
Figure 117: CENTOGENE N.V.: R&D Expenditure, $Million, 2018-2020
Figure 118: CENTOGENE N.V.: SWOT Analysis
Figure 119: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 120: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, $Billion, 2019-2021
Figure 121: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Billion, 2019-2021
Figure 122: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Billion, 2019-2021
Figure 123: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Billion, 2019-2021
Figure 124: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 125: Fulgent Genetics, Inc.: Service Portfolio
Figure 126: Fulgent Genetics, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 127: Fulgent Genetics, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 128: Fulgent Genetics, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 129: Fulgent Genetics, Inc.: SWOT Analysis
Figure 130: Illumina, Inc.: Product Portfolio
Figure 131: Illumina, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 132: Illumina, Inc.: Revenue (by Business Segment), $Million, 2018–2020
Figure 133: Illumina, Inc.: Revenue (by Region), $Million, 2018–2020
Figure 134: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 135: Illumina, Inc.: SWOT Analysis
Figure 136: Invitae Corporation: Service Portfolio
Figure 137: Invitae Corporation: Overall Financials/Revenue, $Million, 2018-2020
Figure 138: Invitae Corporation: Revenue (by Business Segment), $Million, 2018–2020
Figure 139: Invitae Corporation: Revenue (by Region), $Million, 2018-2020
Figure 140: Invitae Corporation: R&D Expenditure, $Million, 2018-2020
Figure 141: Invitae Corporation: SWOT Analysis
Figure 142: Konica Minolta, Inc.: Service Portfolio
Figure 143: Konica Minolta, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 144: Konica Minolta, Inc.: Revenue (by Business Segment), $Million, 2019-2020
Figure 145: Konica Minolta, Inc.: Revenue (by Healthcare Business), $Million, 2019-2020
Figure 146: Konica Minolta, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 147: Konica Minolta, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 148: Konica Minolta, Inc.: SWOT Analysis
Figure 149: Laboratory Corporation of America Holdings: Service Portfolio
Figure 150: Laboratory Corporation of America Holdings: Overall Financials/Revenue, $Million, 2018-2020
Figure 151: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2018-2020
Figure 152: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2018-2020
Figure 153: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 154: Myriad Genetics, Inc.: Service Portfolio
Figure 155: Myriad Genetics, Inc.: Overall Financials/Revenue, 2018-2020
Figure 156: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020
Figure 157: Myriad Genetics, Inc.: SWOT Analysis
Figure 158: OPKO Health, Inc.: Service Portfolio
Figure 159: OPKO Health, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 160: OPKO Health, Inc.: Revenue (by Business Segment), $Million, 2018–2020
Figure 161: OPKO Health, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 162: OPKO Health, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 163: OPKO Health: SWOT Analysis
Figure 164: QIAGEN N.V.: Product Portfolio
Figure 165: QIAGEN N.V.: Overall Financials/Revenue, 2019-2021
Figure 166: QIAGEN N.V.: Revenue (by Segment), 2019-2021
Figure 167: QIAGEN N.V.: Revenue (by Region), 2019-2021
Figure 168: QIAGEN N.V.: R&D Expenditure, 2019-2021
Figure 169: QIAGEN N.V.: SWOT Analysis
Figure 170: Quest Diagnostics Incorporated: Service Portfolio
Figure 171: Quest Diagnostics Incorporated: Overall Financials/Revenue, $Million, 2018-2020
Figure 172: Quest Diagnostics Incorporated: Revenue (by Business Segment), $Million, 2018-2020
Figure 173: Quest Diagnostics Incorporated: SWOT Analysis
Figure 174: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 175: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020
Figure 176: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2018–2020
Figure 177: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018–2020
Figure 178: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
Figure 179: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 180: NgeneBio: Product Portfolio
Figure 181: oncgnostics GmbH: Product Portfolio
Figure 182: Self-screen B.V.: Product Portfolio
Figure 183: Strata Oncology, Inc.: Product Portfolio
List of Tables
Table 1: Risks Associated with the Types of Genes Related to Hereditary Ovarian and Uterine Cancer
Table 2: Advantages and Limitations of Short-Read Sequencing and Long-Read Sequencing
Table 3: National Comprehensive Cancer Network (NCCN) Recommended Predictive Molecular Testing in Gynecological Cancer
Table 4: Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx) for Gynecological Cancers
Table 5: Reimbursement Scenario Across Major Countries
Table 6: Regulatory Framework and Reimbursement Options of NGS-Based Diagnostics Across Major Countries
Table 7: Next-Generation Sequencing Clinical Utility in Gynecological Cancers
Table 8: Services Offered by Key Players
Table 9: Products Offered by Key Players
Companies Mentioned
- Agilent Technologies, Inc.
- ARUP Laboratories
- BGI Genomics
- CENTOGENE N.V.
- F. Hoffmann-La Roche Ltd
- Fulgent Genetics, Inc.
- Illumina, Inc.
- Invitae Corporation
- Konica Minolta, Inc.
- Laboratory Corporation of America Holdings
- Myriad Genetics, Inc.
- OPKO Health, Inc.
- QIAGEN N.V.
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 231 |
| Published | March 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 2167 Million |
| Forecasted Market Value ( USD | $ 5657.7 Million |
| Compound Annual Growth Rate | 10.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
